Drug info - Naproxen pills 500mg

Discussion in 'Various drugs not covered by other forums' started by Guest, May 29, 2004.

Thread Status:
Not open for further replies.
  1. Guest

    Guest Guest

    Reputation Points:
    does anyone know if these will do anything? or any information about what they do would be helpful... do u think if i take a few will i feel somethin?
  2. ShadyMilkman

    ShadyMilkman Mercury Member

    Reputation Points:
    Mar 13, 2004
    Naproxen is an OTC anti-inflammatory, just like advil and ibuprofen, etc. This was discussed in another thread as well. Sorry.

    In short, no, you won't.
  3. enquirewithin

    enquirewithin Gold Member

    Reputation Points:
    Dec 11, 2004
    from bermuda
    Merck Dishonest over Vioxx Heart dangers

    Medical Journal Says Merck Concealed Vioxx Data


    Published: December 8, 2005
    Merck misrepresented the results of a crucial clinical trial of Vioxx to play down the drug's heart risks, The New England Journal of Medicine said today.

    The Journal's allegation may play a critical role in the thousands of lawsuits that Merck faces over Vioxx, a once-popular painkiller that has been linked to heart attacks and strokes. In the three lawsuits that have reached trial so far, Merck has contended that it promptly disclosed information about Vioxx's heart risks.

    But in an interview today, Dr. Gregory D. Curfman, the executive editor of The Journal, sharply criticized Merck for hiding data from the trial. The study, called Vigor, was published in The Journal in November 2000 and covered more than 8,000 patients.

    "They did not disclose all they knew," Dr. Curfman said. "There were serious negative consequences for the public health as a result of that." The Journal is widely read by doctors and scientists, with a circulation of almost 200,000.

    Merck said in a statement that it had acted properly and promptly disclosed the Vigor findings. But lawyers for plaintiffs said they believed that the allegation would undercut the company's defense. Shares of Merck fell sharply after the statement was made public.

    In an "Expression of Concern" posted this afternoon on its Web site, The Journal said the authors of the study had deleted data on strokes and other vascular problems suffered by patients in the Vigor trial two days before it submitted the results to the publication.

    The authors also underreported the number of heart attacks suffered by patients taking Vioxx, claiming that there were 17 heart attacks when there were actually 20, The Journal said. The authors have been asked to correct the study, The Journal said.

    The authors of the Vigor study included both Merck scientists and independent researchers. The study's results showed that patients taking Vioxx were four times as likely to suffer heart attacks as those taking naproxen, an older painkiller. In fact, 20 patients taking Vioxx suffered heart attacks, compared with four taking naproxen, a ratio of five to one.

    Merck said at the time that the difference probably resulted from the fact that naproxen protected people from heart attacks, not because Vioxx caused them. Many independent scientists disputed the company's theory.

    If the authors of the study had published the data about strokes and other vascular problems, the company's theory would have been even harder to accept, Dr. Curfman said.

    "The totality of the data didn't look good for Vioxx," he said.

    More than 20 million Americans took Vioxx between 1999, when Merck began selling the drug, and 2004, when Merck withdrew it from the market after another clinical trial showed that it increased the risk of both heart attacks and strokes.
  4. Abrad

    Abrad R.I.P. Platinum Member & Advisor R.I.P.

    Reputation Points:
    Dec 10, 2005
    Common painkillers 'increase risk of heart failure by a third'

    By Nigel Hawkes, Health Editor
    REGULAR use of painkillers increases the risk of heart failure by 30 per cent, according to a new study.

    Patients with arthritis are commonly prescribed non-steroidal anti-inflammatory drugs (NSAIDs). Typical of the class are ibuprofen, naproxen, diclofenac, indomethacin and meloxicam. The Spanish Centre for Pharmacoepidemiological Studies in Madrid used the UK General Practice Research Database to compare the risks for those taking NSAIDs with those who were not.

    Heart failure, a relatively common condition, especially in the elderly, arises when the heart no longer has the power to pump blood effectively.

    The team reports in Heart that taking NSAIDs increases the risk of getting heart failure by 30 per cent, after other factors are taken into account. It measured admission to hospital with heart failure, information accessible through the database, but was unable to say whether the risk of dying was similarly increased.

    Of all those admitted to hospital with heart failure, 14 per cent were taking NSAIDs, compared with 10 per cent of a randomly selected sample. Half were aged 70 to 79. Of the NSAIDs, indomethacin seems to carry the greatest risk, tripling the chance of hospital admission with heart failure.

    The results mean that, for every 1,000 people aged 60 to 84, taking NSAIDs would lead to one extra hospital admission. This could rise to three among older patients with other health problems such as diabetes, high blood pressure or kidney failure.

    The study does not look at the modern alternatives to NSAIDs, called COX-2 inhibitors. Vioxx, one of this class, has already been withdrawn for increasing the risk of heart attack and stroke in a trial.

    Many patients with osteoarthritis need NSAIDs to make life endurable, so the extra risk of heart failure is unlikely to change their habits. But the study does emphasise the need for powerful painkillers with fewer side-effects.

    Too few British people are given statin drugs to make much impact on death rates, a study reported in Heart has shown. Statins, cholesterollowering drugs that are highly effective at cutting death rates, are currently prescribed only for relatively high-risk patients — those who have had a previous heart attack or stroke, or whose cholesterol levels are higher than normal.

    To have a significant effect on deaths, as many as three quarters of middle-aged men need to be prescribed the drugs, according to the team led by Paul Durrington, of Manchester Royal Infirmary.
  5. Abrad

    Abrad R.I.P. Platinum Member & Advisor R.I.P.

    Reputation Points:
    Dec 10, 2005
    Popular pain drug increases heart risk

    Clara Pirani, Medical reporter
    May 23, 2006
    REGULAR use of popular painkillers including Nurofen and Voltaren increases the risk of heart failure by 30 per cent.

    The new research, published yesterday in the online version of the British Medical Journal, is the third study in less than a year to link the painkillers to heart disease.

    "Based on previous studies we know there's an increased risk of cardiovascular complications associated with all the non-steroidal anti-inflammatory drugs," said Jo-Dee Lattimore, a cardiologist at Royal Prince Alfred Hospital in Sydney.

    "This study confirms what we've suspected."

    In June last year, a British study of more than 9000 people who had suffered a heart attack found several commonly used painkillers increased the risk ofan attack by between 24 to 55per cent.

    In November, a Danish study of 58,000 men showed that use of the pain-relievers - known as non-steroidal anti-inflammatory drugs (NSAIDs) - after a heart attack increased the risk of death.

    In the latest study, researchers from the Spanish Centre for Pharmacoepidemiologic Research in Madrid reviewed the patient records of more than 228,660 patients on January 1, 1997, and monitored the patients until the end of 2000.

    Researchers took into account factors that would increase the risk of heart failure including obesity, smoking and a history of heart disease.

    They found that 14 per cent of patients admitted to hospital for heart failure were taking NSAIDs, compared with 10 per cent of a control group who did not suffer heart failure.

    The researchers concluded that NSAIDs not only exacerbate symptoms of heart failure among patients with a history of cardiovascular disease, but also trigger "the risk of heart failure hospitalisation in patients without a history of clinical heart failure".

    In June 2004, medications watchdog the Therapeutic Goods Administration ruled that ibuprofen, most commonly sold as Nurofen, could be sold outside pharmacies.

    Gregory Peterson, a researcher from the University of Tasmania's school of pharmacy, said the TGA should reverse that decision.

    "It's too dangerous for these drugs to be available in supermarkets," he said. "The decision to make them available in supermarkets was made several years ago and there's been a lot of new evidence about their safety gathered since then."

    A TGA spokeswoman said the regulator was aware of ongoing concerns about the safety of NSAIDs.

    "The TGA and other regulators are reviewing the safety of NSAIDs," she said.

    "The TGA will also consider the findings of the Food and Drug Administration's review of NSAIDs (not yet completed) when making a decision on the possible implementation of cardiovascular warnings."

    A spokeswoman for Reckitt Benckiser, which makes Nurofen, said the study involved NSAIDs available on prescription, not over the counter.

    "Ibuprofen is a highly effective pain medicine that has been used safely in more than 50 countries worldwide and by millions of people," said Zephanie Jordan, director of pharmaceutical regulatory and external affairs. "There is a considerable body of scientific evidence illustrating the safety and efficacy of ibuprofen when used at low doses and for short-term use."

    Anti-inflammatory medication Vioxx was withdrawn from sale in September 2004 after it was found to increase the risk of heart attacks.
  6. Abrad

    Abrad R.I.P. Platinum Member & Advisor R.I.P.

    Reputation Points:
    Dec 10, 2005
    Painkillers 'increase risk of heart failure'


    TAKING commonly-used painkillers could increase the risk of heart failure in the elderly by almost a third, according to new research.

    The study, involving the medical records of millions of patients across the UK, found that drugs such as ibuprofen raised the risk of someone being admitted to hospital with heart failure for the first time by 30 per cent.

    The researchers, led by Dr Consuelo Huerta, identified all patients aged 60 to 84 on 1 January, 1997. They were then monitored up to the end of 2000.

    Several factors increased the risk of being admitted to hospital with heart failure for the first time, including obesity, smoking and other medical problems.

    But the researchers also noted that 14 per cent of patients were taking prescription non-steroidal anti-inflammatory drugs (NSAIDs) at the time they were admitted to hospital. This compared to 10 per cent of a control group who did not suffer heart failure.

    Those patients taking the drug indomethacin appeared to face the greatest risk - they were more than three times as likely to be admitted to hospital for heart failures than those not taking the drug.

    The researchers said the figures suggested that there would be just one extra first case of hospital admission for heart failure for every 1,000 people aged 60 to 84 taking NSAIDs. But they said this could rise to three additional cases per 1,000 in patients aged 70 and older with conditions such as diabetes, high blood pressure or kidney failure.

    The researchers, from Madrid, said although the overall risk may appear small, it may have a considerable impact on public health.

    The researchers said: "Heart failure is a common cause of morbidity and mortality in the elderly and even a small increase in the risk can translate into a significant disease burden in the general population."

    June Davison, medical spokeswoman for the British Heart Foundation, said the study confirmed that the use of NSAIDs may increase symptoms in people who have heart failure.

    She said: "Many people who are prescribed this medication suffer debilitating pain from inflammatory diseases, such as rheumatoid arthritis. These people may consider the possible slight increase in risk of heart failure symptoms to be acceptable."

    A spokesman for the International Ibuprofen Foundation said: "This study is concerned with long-term prescription use of ibuprofen in patients aged 60 to 84. It would therefore not apply to the general public and certainly not to over-the-counter use of ibuprofen."

    • Britons are currently so unhealthy that much of the population would have to take cholesterol-lowering drugs to make a significant impact on rates of heart disease, say researchers in the journal Heart.

    Statins, which are highly effective at cutting cholesterol levels, are reserved only for high-risk patients in the UK.
  7. HandyMan81

    HandyMan81 Titanium Member

    Reputation Points:
    Dec 7, 2005
    from The Netherlands
    Aleve Newest Drug Linked To Risk

    (CBS/AP) A recent study has raised questions about the safety of the over-the-counter pain reliever naproxen, commonly known under the brand name Aleve, which has been in use for 28 years.

    The study, a large exploration into treatments for Alzheimer's Disease, has since been suspended. Researchers found patients taking naproxen had more heart attacks and strokes than others.

    The study, involving some 2,500 patients, was to test whether naproxen or Celebrex, both pain relievers, could reduce the risk of Alzheimer's Disease among healthy elderly patients who were at an increased risk of the disease.

    Officials at the said the study was suspended after three years when it was found that patients taking naproxen had a 50 percent greater incidence of cardiovascular events — heart attack or stroke — than patients taking placebo.

    Another factor, officials said, was the announcement last week that advertising for Celebrex was being halted after a study found that high doses of the drug were associated with an increase in heart attack risk. Preliminary data from the Alzheimer's study, however, did not indicate an increased risk for heart attack or stroke for Celebrex, officials said.

    With these warning signs against popular medications, many patients, such as arthritis sufferer 78-year old Ruth Birn, are left wondering what their options are. CBS News Correspondent Elizabeth Kaledin talked with Birn, who said, "I'm concerned, but what else am I going to take?"

    Although much of the evidence against the popular drugs hasn't turned into formal warnings against their use, Dr. Elias Zerhouni, the head of the National Institues of Health, advises using caution if perscribed one of the recently criticized drugs.

    "My advice I would give to the public is this: do not use these drugs for longer than you need them at doses higher than are recommended," Zerhouni said.

    Despite this and other news showing the danger of popular medications and directing scrutiny at the FDA, most Americans say they're at least somewhat confident about the safety of prescription drugs sold in the United States, according to an Associated Press poll taken at a time when several popular medications have been linked to increased risk of heart attack and stroke.

    Just more than eight in 10 said they have confidence in the general safety of prescription drugs in this country, the poll conducted for the AP by Ipsos-Public Affairs found. Almost that many said they have confidence in the FDA.

    Celebrex, a prescription drug, and naproxen are both commonly used to treat the joint pain of arthritis. Naproxen has been approved for sale, first as a prescription and then as an over-the-counter drug, since 1976. Celebrex is in the same class — COX2 enzyme inhibitors — as Vioxx, an arthritis drug recently taken off the market by its manufacturer after it was linked to an increase in heart attack and stroke.

    The FDA plans a meeting in February to get to bottom of the COX2 problem, reports CBS News Medical Correspondent Dr. Elizabeth Kaledin. The hope is the public will soon have an answer whether these drugs do more harm than good.

    "What this kind of information does is kind of raise a flag that says be careful with drugs," Stuart Schweitzer, a professor of health services at UCLA and a specialist in pharmaceutical policy, told CBS Radio News. "There aren't any completely innocuous drugs.

    "It appears to be getting more and more difficult to find really safe drugs for common diseases," Schweitzer said.

    Dr. Sandra Kweder of the Food and Drug Administration said the NIH study is the first to show that naproxen might increase the risk of heart attack or stroke and that the findings are "confusing." No immediate action, however, is expected toward naproxen, she said.

    "We are not contemplating any specific regulatory action over the next few days," said Kweder. "We will be working with the NIH to try to understand the data better and determine what will be appropriate from there."

    She said patients who routinely take naproxen should follow the drug package instructions carefully, including the directions to not take it for more than 10 days, and to consult a doctor if pain persists.

    "If a patient needs a drug and derives a lot of benefit from it, and if the absolute risk of this side effect is still small, then the advice probably should be to continue using that drug," said Schweitzer.

    Otherwise, "I guess we go back to aspirin, and there the problem is that some patients do have a gastric, a stomach reaction," he added.

    In the earlier studies of the COX2 drugs, an increase in cardiovascular events was noted only after a long-term use of the medications.

    The Alzheimer's disease study was being conducted by the National Institute on Aging, an arm of the NIH. It called for 2,500 patients aged 70 or older and who had a family history of Alzheimer's, to take either Celebrex, naproxen or a placebo.

    The group was divided and each division, or arm, was assigned to receive one of the drugs or placebo. The drugs were blinded, which means the patients did not know which medication they were taking, or if they were taking a placebo.

    The goal was to determine if the pain-relieving drugs lowered the risk of developing Alzheimer's disease. The study started three years ago and was to continue for a few more years. Officials said the patients in the study will be monitored for developing Alzheimer's or cognitive decline, but will not be given the test drugs.

    John Breitner of the Veterans Affairs medical facility in Seattle and the University of Washington, an investigator in the trial, said only preliminary data is available. But he said it suggests that among the 2,500 patients in the study, about 70 suffered stroke or heart attack. There were 23 deaths. There were 50 percent more of the cardiovascular events among patients taking naproxen than among those taking placebo, he said.

    "With Naproxen, we've been doing very large clinical trials, and large clinical trials tend to uncover side effects that were there all along, but we didn't notice them," said Schweitzer.

    Last edited by a moderator: Sep 10, 2017
Thread Status:
Not open for further replies.